CAMBRIDGE: AstraZeneca, a global, science-led biopharmaceutical company, has launched a health tech business, Evinova, to accelerate innovation across the life sciences sector, the delivery of clinical trials, and better health outcomes.
According to a statement by AstraZeneca, Evinova is set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients.
“We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale provides a real opportunity to fundamentally improve patient care, drive healthcare transformation, and reduce carbon emissions,” said AstraZeneca chief executive officer, Pascal Soriot.
Meanwhile, Evinova president Cristina Duran said, “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community.”
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.
Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery, thus minimising the time and cost of developing new medicines, bringing care closer to home for patients, and reducing the burden on health systems.
In addition, Evinova will pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of innovations in these areas.
Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and artificial intelligence, user experience design, and behavioural science.